Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
<p><strong>Objective:</strong> Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
John Wiley and Sons, Ltd.
2018
|
| _version_ | 1826297348734582784 |
|---|---|
| author | Tanaka, Y McInnes, I Taylor, P Byers, N Chen, L de Bono, S Issa, M Macias, W Rogai, V Rooney, T Schlichting, D Zuckerman, S Emery, P |
| author_facet | Tanaka, Y McInnes, I Taylor, P Byers, N Chen, L de Bono, S Issa, M Macias, W Rogai, V Rooney, T Schlichting, D Zuckerman, S Emery, P |
| author_sort | Tanaka, Y |
| collection | OXFORD |
| description | <p><strong>Objective:</strong> Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes with clinical outcomes of baricitinib treatment.</p> <p><strong>Methods:</strong> An integrated analysis was conducted by pooling data from three completed Phase 3 trials comparing placebo and baricitinib treatment (RA-BEAM, RA-BUILD, and RA-BEACON) and one ongoing long-term extension study (RA-BEYOND) in patients (N=2,186) with active RA.</p> <p><strong>Results:</strong> Baricitinib treatment was associated with an early transient increase in total lymphocyte count at week 4, which returned to baseline by week 12. Transient changes within normal reference ranges in T cells and subsets were observed with baricitinib treatment. B cells and relevant subpopulations increased after 4 weeks of baricitinib treatment with no further increases noted through 104 weeks of treatment. Natural killer (NK) cells transiently increased after 4 weeks of baricitinib treatment, before decreasing below baseline levels and then stabilizing over time. Few correlations were observed between changes in lymphocyte subsets and clinical endpoints with baricitinib treatment, and most were also observed within the placebo arm. A modest potential association was observed for baricitinib 4-mg between low NK cells and treatment emergent infections but not serious infections or herpes zoster.</p> <p><strong>Conclusion:</strong> Overall, changes in lymphocyte subsets were largely within normal reference ranges across the baricitinib Phase 3 RA clinical program, and were not associated with increased risk of serious infections.</p> |
| first_indexed | 2024-03-07T04:30:14Z |
| format | Journal article |
| id | oxford-uuid:ce0aca2b-d59a-4549-8a52-7f0315b79753 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T04:30:14Z |
| publishDate | 2018 |
| publisher | John Wiley and Sons, Ltd. |
| record_format | dspace |
| spelling | oxford-uuid:ce0aca2b-d59a-4549-8a52-7f0315b797532022-03-27T07:33:05ZCharacterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ce0aca2b-d59a-4549-8a52-7f0315b79753Symplectic Elements at OxfordJohn Wiley and Sons, Ltd.2018Tanaka, YMcInnes, ITaylor, PByers, NChen, Lde Bono, SIssa, MMacias, WRogai, VRooney, TSchlichting, DZuckerman, SEmery, P<p><strong>Objective:</strong> Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes with clinical outcomes of baricitinib treatment.</p> <p><strong>Methods:</strong> An integrated analysis was conducted by pooling data from three completed Phase 3 trials comparing placebo and baricitinib treatment (RA-BEAM, RA-BUILD, and RA-BEACON) and one ongoing long-term extension study (RA-BEYOND) in patients (N=2,186) with active RA.</p> <p><strong>Results:</strong> Baricitinib treatment was associated with an early transient increase in total lymphocyte count at week 4, which returned to baseline by week 12. Transient changes within normal reference ranges in T cells and subsets were observed with baricitinib treatment. B cells and relevant subpopulations increased after 4 weeks of baricitinib treatment with no further increases noted through 104 weeks of treatment. Natural killer (NK) cells transiently increased after 4 weeks of baricitinib treatment, before decreasing below baseline levels and then stabilizing over time. Few correlations were observed between changes in lymphocyte subsets and clinical endpoints with baricitinib treatment, and most were also observed within the placebo arm. A modest potential association was observed for baricitinib 4-mg between low NK cells and treatment emergent infections but not serious infections or herpes zoster.</p> <p><strong>Conclusion:</strong> Overall, changes in lymphocyte subsets were largely within normal reference ranges across the baricitinib Phase 3 RA clinical program, and were not associated with increased risk of serious infections.</p> |
| spellingShingle | Tanaka, Y McInnes, I Taylor, P Byers, N Chen, L de Bono, S Issa, M Macias, W Rogai, V Rooney, T Schlichting, D Zuckerman, S Emery, P Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title | Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title_full | Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title_fullStr | Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title_full_unstemmed | Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title_short | Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
| title_sort | characterization and changes of lymphocyte subsets in baricitinib treated patients with rheumatoid arthritis an integrated analysis |
| work_keys_str_mv | AT tanakay characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT mcinnesi characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT taylorp characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT byersn characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT chenl characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT debonos characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT issam characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT maciasw characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT rogaiv characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT rooneyt characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT schlichtingd characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT zuckermans characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis AT emeryp characterizationandchangesoflymphocytesubsetsinbaricitinibtreatedpatientswithrheumatoidarthritisanintegratedanalysis |